Paweł Kawalec

Summary

Affiliation: Jagiellonian University
Country: Poland

Publications

  1. doi request reprint Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Krakow, Poland Electronic address
    Health Policy . 2016
  2. doi request reprint Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Science, Institute of Public Health, Poland Electronic address
    Health Policy 120:356-61. 2016
  3. pmc Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland
    Paweł Kawalec
    Faculty of Health Science, Institute of Public Health, Jagiellonian University Medical College, Grzegorzecka 20, 31 531, Krakow, Poland
    Rheumatol Int 36:1223-30. 2016
  4. pmc The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, ul Grzegorzecka 20, 31 531, Krakow, Poland
    Orphanet J Rare Dis 11:122. 2016
  5. doi request reprint Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Department of Drug Management, Krakow, Poland Electronic address
    Clin Breast Cancer 15:90-100.e1. 2015
  6. doi request reprint Pregabalin for the treatment of social anxiety disorder
    Paweł Kawalec
    Jagiellonian University Medical College, Department of Drug Management, Faculty of Health Sciences, Grzegorzecka 20, PL 31 531 Kraków, Poland
    Expert Opin Investig Drugs 24:585-94. 2015
  7. pmc Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland
    Arch Med Sci 8:767-75. 2012
  8. pmc The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, 20 Grzegorzecka St, 31 531, Krakow, Poland
    Clin Rheumatol 32:1415-24. 2013
  9. ncbi request reprint [Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Wydział Nauk o Zdrowiu, Instytut Zdrowia Publicznego, Zaklad Gospodarki Lekiem
    Pol Merkur Lekarski 35:10-3. 2013
  10. ncbi request reprint [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu
    Pol Merkur Lekarski 34:332-8. 2013

Collaborators

  • Gabriel Nowak
  • Maria Boratynska
  • Paweł Moćko
  • Andrzej Pilc
  • Ewa Stawowczyk
  • Krzysztof Piotr Malinowski
  • Przemysław Holko
  • Joanna Kryst
  • Nevena Sović
  • Małgorzata Mossakowska
  • Wojciech Trabka
  • Beata Smela-Lipińska
  • Renata Wolfshaut-Wolak
  • Kalina Kawecka-Jaszcz
  • Alejandra Duenas
  • Piotr Jankowski
  • Urszula Stepaniak
  • Andrzej Pajak

Detail Information

Publications35

  1. doi request reprint Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Krakow, Poland Electronic address
    Health Policy . 2016
    ....
  2. doi request reprint Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Science, Institute of Public Health, Poland Electronic address
    Health Policy 120:356-61. 2016
    ..This paper analyses the main changes introduced by the Reimbursement Act and their implications. Since the Act came into force relatively recently, its full impact on the reimbursement policy is not yet possible to assess. ..
  3. pmc Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland
    Paweł Kawalec
    Faculty of Health Science, Institute of Public Health, Jagiellonian University Medical College, Grzegorzecka 20, 31 531, Krakow, Poland
    Rheumatol Int 36:1223-30. 2016
    ..Total indirect costs were negatively correlated with utility. The greater the disease activity, the lower the utility and the greater the indirect costs. ..
  4. pmc The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, ul Grzegorzecka 20, 31 531, Krakow, Poland
    Orphanet J Rare Dis 11:122. 2016
    ..Separate calculations were also performed for three sub-groups: ultra-orphan drugs, oncology orphan drugs and other (non-ultra, non-oncology) orphan drugs...
  5. doi request reprint Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Department of Drug Management, Krakow, Poland Electronic address
    Clin Breast Cancer 15:90-100.e1. 2015
    ..The addition of targeted therapy to chemotherapy or endocrine therapy using HER2 and HR status significantly improved ORR, PFS, and OS in patients with previously untreated MBC...
  6. doi request reprint Pregabalin for the treatment of social anxiety disorder
    Paweł Kawalec
    Jagiellonian University Medical College, Department of Drug Management, Faculty of Health Sciences, Grzegorzecka 20, PL 31 531 Kraków, Poland
    Expert Opin Investig Drugs 24:585-94. 2015
    ..However, new effective therapeutic options are still needed. Pregabalin is a novel anxiolytic, which seems to be a promising therapy for SAD...
  7. pmc Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland
    Arch Med Sci 8:767-75. 2012
    ..It is assumed to be associated with less adverse events than conventional docetaxel-based chemotherapy...
  8. pmc The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, 20 Grzegorzecka St, 31 531, Krakow, Poland
    Clin Rheumatol 32:1415-24. 2013
    ..In addition, tofacitinib might provide an effective treatment option compared to intravenous or subcutaneous biological DMARDs, as suggested by the result of the comparison made regarding tofacitinib vs. adalimumab ACR50 response rate...
  9. ncbi request reprint [Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Wydział Nauk o Zdrowiu, Instytut Zdrowia Publicznego, Zaklad Gospodarki Lekiem
    Pol Merkur Lekarski 35:10-3. 2013
    ....
  10. ncbi request reprint [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu
    Pol Merkur Lekarski 34:332-8. 2013
    ..z o.o.) from 110 to 200 days, in the high risk patients group after kidney transplant (seronegative recipient and infected donor, D+/R-). The analysis was performed from the Polish healthcare payer's perspective...
  11. doi request reprint Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis
    Paweł Moćko
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
    Pharmacol Rep 68:1237-1243. 2016
    ..Crohn disease (CD) is an inflammatory bowel disease which occurs especially in developed countries of Western Europe and North America. The aim of the study was to compare the safety profile of biologic drugs in patients with CD...
  12. doi request reprint Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting
    Paweł Kawalec
    Departament of Drug Management, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Krakow, Poland
    Kardiol Pol 73:768-80. 2015
    ..The current ESC/ESH 2013 guidelines for the first time recommend treatment with a combination of thiazide-like diuretic with calcium channel blocker. Currently, no such combination is reimbursed from public funds in Poland...
  13. pmc Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
    Paweł Moćko
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
    Arch Med Sci 12:1088-1096. 2016
    ..The aim of this systematic review (SR) and meta-analysis was to assess the efficacy and safety of vedolizumab in the treatment of Crohn's disease (CD)...
  14. pmc Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland
    Przemysław Holko
    Drug Management Department, Jagiellonian University Medical College, Krakow, Poland
    PLoS ONE 11:e0168586. 2016
    ..In the present study, the quality of life and indirect costs of CD patients were assessed (overall and by disease severity)...
  15. doi request reprint Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
    Paweł Moćko
    Drug Management Department, Faculty of Health Sciences, Institute of Public Health, Jagiellonian University, ul Grzegorzecka 20, 31 531, Krakow, Poland
    Clin Drug Investig 37:25-37. 2017
    ..Biologic drugs are used in innovative therapies for the management of inflammatory bowel diseases (IBDs). The aim of this study was to compare the safety profile of biologic drugs in patients with IBD...
  16. pmc Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
    Ewa Stawowczyk
    StatSoft Polska Sp z o o, Krakow, Poland
    Eur J Clin Pharmacol 72:1319-1325. 2016
    ..The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with adalimumab/standard care and standard care alone in Poland...
  17. pmc Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
    Ewa Stawowczyk
    StatSoft Polska Sp z o o, Krakow, Poland
    PLoS ONE 11:e0160444. 2016
    ..The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with golimumab/standard care and standard care alone in Poland...
  18. doi request reprint Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis
    Paweł Moćko
    Department of Drug Management, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland
    Pharmacotherapy 36:870-9. 2016
    ..We compared the safety profile of biologic drugs in patients with moderately to severely active ulcerative colitis (UC)...
  19. doi request reprint Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland
    Ewa Stawowczyk
    StatSoft Polska Sp z o o, Krakow, Poland
    Pharmacotherapy 36:472-81. 2016
    ..g., azathioprine, prednisolone, mesalazine, and 6-mercaptopurine) versus standard care alone for induction and maintenance treatment of patients with ulcerative colitis (UC) in Poland...
  20. doi request reprint The indirect costs of multiple sclerosis: systematic review and meta-analysis
    Ewa Stawowczyk
    a 1 HTA Expert, Krakow, 31 531, Poland
    Expert Rev Pharmacoecon Outcomes Res 15:759-86. 2015
    ..Costs were higher for Europe than for other continents and were also higher for patients with a higher Expanded Disability Status Scale score. ..
  21. pmc Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Joanna Kryst
    Independent EBM expert, Krakow, Poland
    PLoS ONE 10:e0124279. 2015
    ..Beneficial safety profile of InSTI-based and CCR5-based therapy over efavirenz-based treatment needs further studies. ..
  22. pmc Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland Centrum HTA Sp z o o Sp komandytowa, Krakow, Poland
    PLoS ONE 8:e76587. 2013
    ..Nevirapine belongs to the group of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is commonly administered in first-line treatment of HIV infection...
  23. doi request reprint Health utility of patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis
    Krzysztof Piotr Malinowski
    a Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Krakow, Poland
    Expert Rev Pharmacoecon Outcomes Res 16:441-53. 2016
    ..The aim of this systematic review was to collect and summarize the current data on the utilities of patients with Crohn's disease (CD) and ulcerative colitis (UC)...
  24. doi request reprint Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
    Pharmacotherapy 36:861-9. 2016
    ..The purpose of this analysis was to compare the efficacy and safety of vedolizumab and certolizumab pegol in patients with active moderate to severe CD...
  25. doi request reprint Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis
    Paweł Kawalec
    Faculty of Health Science, Jagiellonian University Medical College, Institute of Public Health, Grzegorzecka 20, 31 531 Krakow, Poland
    Expert Rev Pharmacoecon Outcomes Res 15:253-66. 2015
    ....
  26. doi request reprint The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis
    Krzysztof Piotr Malinowski
    Jagiellonian University Medical College, Faculty of Health Science, Institute of Public Health, Grzegorzecka 20, Krakow, 31 232, Poland
    Expert Rev Pharmacoecon Outcomes Res 15:285-300. 2015
    ..We observed a great variety of the considered components of indirect costs and their definitions. ..
  27. doi request reprint The indirect costs of psoriatic arthritis: systematic review and meta-analysis
    Paweł Kawalec
    Department of Drug Management, Institute of Public Health, Faculty of Health Science, Jagiellonian University Medical College, Grzegorzecka 20, 31 531 Krakow, Poland
    Expert Rev Pharmacoecon Outcomes Res 15:125-32. 2015
    ..04 per patient per year in 2013 prices. This systematic review revealed a great economic burden of the disease to the society. A small number of studies on IC in PsA justify further investigations. ..
  28. pmc An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
    Arch Med Sci 12:1097-1109. 2016
    ..The aim of the study was to compare adalimumab or golimumab with infliximab in patients with moderately-to-severely active ulcerative colitis (UC)...
  29. doi request reprint Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014
    Krzysztof Piotr Malinowski
    Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Krakow, Poland
    Health Policy 120:1249-1255. 2016
    ..5) and the general cost of therapy (odds ratio of 3) in the analysed period...
  30. ncbi request reprint [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results]
    Paweł Kawalec
    Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu UJ, ul Grzegorzecka 20, Krakow
    Pneumonol Alergol Pol 81:95-104. 2013
    ..The aim of this study is a comparison of the clinical effectiveness of conestat alfa, human C1 esterase inhibitor (C1INH), and icatibant in the treatment of acute angioedema attacks in adults with HAE...
  31. doi request reprint Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project
    Nevena Sović
    Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Krakow, Poland
    Kardiol Pol 71:702-11. 2013
    ..However, introducing them broadly into clinical practice would have a significant impact on the healthcare budget, and requires careful consideration...
  32. doi request reprint Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
    Przemysław Holko
    Centrum HTA, Krakow, Poland
    Expert Rev Anticancer Ther 14:63-73. 2014
    ..Accounting for crossover treatment in control patients improves sipuleucel-T's value (US$132,000 per QALY saved) although further investigation is necessary. ..